French biotech HEPHAISTOS-Pharma gets €4.5 million to develop next-gen of immunostimulants against cancer

Published on May 16, 2024

HEPHAISTOS-Pharma, a biotechnology company developing next generation immunotherapies against cancer targeting innate immunity to increase the cure rate of patients, has completed its €4.5 million seed round to finance industrialization and advance its lead candidate ONCO-Boost towards the clinic. Elaia leads a consortium previously initiated by xista science ventures, the Fondation Fournier-Majoie and Noshaq. Florian…

This content is for members only. Visit the site and log in/register to read.

The post French biotech HEPHAISTOS-Pharma gets €4.5 million to develop next-gen of immunostimulants against cancer appeared first on EU-Startups.

Continue reading on website
Other news

Tallinn-based medtech Nanordica Medical raises €1.75 million to treat severe wounds with nanotechnology

May 16, 2024
Estonian medtech company Nanordica Medical has raised €1.75 million to enter the market with first-in-class wound care products curing severe wounds. The round was led by Estonian fund Specialist VC, with participation from Superangel and Amalfi. 100 million patients suffer from chronic wounds such as diabetic foot, venous leg and pressure ulcers. Moreover, the prevalence… This content is for memb

Berlin-based Caeli Wind snaps €11 million Series A to expand its digital platform for wind energy sites

May 16, 2024
Caeli Wind, a platform for analysing and marketing wind energy locations founded by Ben Schlemmermeier and Heiko Bartels in 2022, announced that it has secured €11 million in growth capital from international investors. The round was led by renowned UK venture capital fund Notion Capital with the participation of Santander Alternative Investments and existing investors… This content is for members